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Vitamin C in the Treatment of Septic Shock
Aly Shaughnessy and Matt Tieszen
James Madison University
December 12, 2018

ABSTRACT
Objective: To assess the efficacy of improving outcomes of septic shock treatment with the
addition of Vitamin C to standard treatment compared to standard therapy alone. To assess
whether or not Vitamin C has a favorable outcome in the treatment of septic shock in terms
of decreasing duration of vasopressor usage, reducing duration of intensive care unit (ICU)
stay, and improving mortality.
Design: Systematic literature review.
Methods: Searches were conducted in PubMed and Google Scholar using the terms ascorbic
acid, sepsis, septic shock, and vasopressors. In PubMed the following filters were used:
humans only, clinical trials, studies within the past 10 years. Studies that used Vitamin C for
the treatment of septic shock and measured the duration of vasopressor usage, total
duration of ICU stay, and mortality were included in the review.
Results: All three studies showed a statistically significant reduction in the duration of
vasopressor dependency with the addition of Vitamin C to the standard treatment of septic
shock. There were conflicting results on the effects on mortality and duration of ICU stay.
Conclusion: The addition of Vitamin C may decrease the duration of vasopressor usage in
the treatment of septic shock. Additional higher-powered studies are needed to determine
the effects of Vitamin C on mortality and duration of ICU stay.
INTRODUCTION
Sepsis is a major public health concern affecting 1.5 million Americans annually and
resulting in 250,000 deaths per year.1 It is defined as life-threatening organ dysfunction
caused by a dysregulated host response to infection.2 Patients with suspected sepsis can
present with fever, tachycardia, hypotension, and leukocytosis. The most common sites of
infection leading to sepsis include the lungs, abdomen, pelvis, and urinary tract.3 A diagnosis
of sepsis is often based upon clinical features combined with blood cultures indicating an
infection. Systemic inflammatory response syndrome (SIRS) criteria is commonly used to
identify patients with suspected sepsis. Table 1 illustrates the criteria for SIRS.
Sepsis progresses to septic shock when there is evidence of organ dysfunction and
tissue hypoperfusion as evidenced by hyperlactemia or failure to respond to fluid
resuscitation. As the infection progresses there is massive systemic vasodilation due to the
release of bacterial endotoxin, resulting in distributive shock. Because of this massive
vasodilation, vasopressors are required in septic shock to maintain a mean arterial pressure
≥65 mmHg.4 Vasopressors are a group of medicines that cause vasoconstriction and are
used to treat severely low blood pressure. Commonly used vasopressors include
epinephrine, norepinephrine, and dobutamine, which work on adrenergic receptors.
Potential harms related to extended duration of vasopressor usage include potentially fatal
tachyarrhythmias and severe vasoconstriction leading to peripheral limb ischemia and
critical limb ischemia.5
The Sequential Organ Failure Assessment (SOFA) score is the primary scoring
system used to assess organ dysfunction and failure in septic patients. A high SOFA score
reflects increasing organ dysfunction. Table 2 illustrates criteria used to calculate a SOFA
score. Patients with a SOFA score ≥2 who require vasopressors and have a lactate of >2
mmol/L have a predicted mortality of 40%.2 Higher SOFA scores are associated with
increased morbidity and mortality in septic patients. The current treatment for septic shock
includes admission to the ICU and subsequent resuscitation of the vasculature with
intravenous (IV) fluids and vasopressors. Empiric treatment with antibiotics to cover all
likely pathogens is started promptly after the diagnosis of sepsis. Despite this intensive
treatment, the in-hospital mortality rate for septic patients is near 30%.1

Clinical studies have revealed that septic patients often present with
hypovitaminosis C due to increased oxidative stress from infection. Oxidative stress in
sepsis is due to an imbalance between antioxidant defense effectiveness and reactive
species generation. This results in a build up of oxidants in the cell which impairs the
mitochondria’s ability to utilize oxygen, ultimately leading to cell and tissue hypoxia.6 The
enzymes involved in the synthesis of endogenous norepinephrine and vasopressin require
ascorbate as a cofactor for optimal activity.7 Thus, it is thought that supplementing patients
in septic shock with high doses of vitamin C will improve hemodynamic instability, the need
for exogenous vasopressin, and potentially decrease overall mortality. The aim of this
review is to evaluate the effects of supplementing patients in septic shock with Vitamin C on
the duration of vasopressor usage, mortality, and the length of ICU stay.
The Systemic Inflammatory Response Syndrome (SIRS)
Two or more of the following:
·

Temperature >38 degrees C or <36 degrees C

·

Heart rate >90 beats/min

·

Respiratory rate >20 breaths/min or PaCO2 <32 torr

·

WBC >12,000 cell/mm, <4,000 cells/mm, or >10% immature (band) forms

Table 1. SIRS clinical criteria used to determine risk for sepsis8
WBC= white blood cells
SOFA Score
Variables

0

1

2

3

4

Respiratory
PaO2/FIO2,mmHg

>400

≤400

≤300

≤200

≤100

Coagulation
Platelets x 10^3/ul

>150

≤150

≤100

≤50

≤20

Liver
Bilirubin, mg/dl

<1.2

1.2-1.9

2.0-5.9

6.0-11.9

>12.0

Cardiovascular
Hypotension

No
hypotension

Mean arterial
pressure <70

Dop ≤5 or
dob (any
dose)

Dop >5, epi
≤0.1, or norepi
≤0.1

Dop >15, epi
>0.1, or norepi
>0.1

CNS
Glasgow Coma Score
Scale

15

13-14

10-12

6-9

<6

Renal
Creatinine, mg/dL
Or urine output,
mL/dL

<1.2

1.2-1.9

2.0-3.4

3.5-4.9 or <500

>5.0 or <200

Table 2. Sequential organ failure assessment criteria from Jones et al.9 Dop=dopamine.
Dob=dobutamine. Epi=epinephrine. Norepi=norepineprine.

PICO
Population: Individuals in the ICU with septic shock
Intervention: Vitamin C plus standard septic shock therapy
Comparison: Standard septic shock therapy
Outcome: Vasopressor duration, mortality, duration of ICU stay
CLINICAL QUESTION
Among individuals in the ICU with septic shock, does Vitamin C plus standard septic shock
therapy as compared to standard septic shock therapy alone reduce the duration of
vasopressor dependency, improve mortality, and reduce the duration of the ICU stay?
METHODS
In September of 2017, a literature review search was conducted using PubMed and
Google Scholar to identify studies that evaluated the use of Vitamin C for the treatment of
sepsis. The following search terms were used: “ascorbic acid” and “sepsis”. Within PubMed,
these two words identified 149 articles. Next, restrictions were added to exclude articles
that were not written within the last 10 years, which narrowed the search to 77 articles to
be screened. Of these 77 articles, 67 were excluded because they were either not human
studies or not clinical trials. The remaining 10 articles were narrowed down to 2 articles
based on outcomes measuring duration of vasopressor usage and mortality.
An additional
literature review
search was done using
Google Scholar with
the terms mentioned
previously in addition
to “septic shock” and
“vasopressor”. This
search yielded 1200
results. Only articles
written within the last
10 years were
included which
narrowed the results
to 636. Within Google
Scholar, the articles
were sorted by date
and did not include
citations or patents,
which resulted in two
articles to be
reviewed. The other
article was not
included as it was not
a clinical trial.
Figure 1. PRISMA flow diagram depicting the literature review
resulting in the three studies evaluated10

An overview of the studies included in the review can be found in Table 3. The three
articles included in this literature review examined the use of Vitamin C in the treatment of
septic shock. All three studies measured the duration of vasopressor dependency, overall
mortality, and the duration of the ICU stay.

RESULTS

Overview of Studies Included in Review
Study 1: Marik et al

Study 2: Zabet et al

Study 3: Habib et al

Year published

2016

2016

2017

Sample Size

94

28

100

Journal

CHEST journal

Journal of Research
in Pharmacy Practice

International Journal
of Microbiology &
Advanced
Immunology (IJMAI)

Study Design

Retrospective
before-after

Double-blinded
Randomized
controlled trial

Randomized
controlled trial

Duration of Study

7 months

17 months

Not specified

Efficacy Outcomes

Hospital mortality,
Duration of
vasopressor use;
duration of ICU stay

Primary Vasopressor dose
and duration,
Secondary - Duration
of ICU stay, 28 day
mortality

Duration of
Vasopressor use;
ICU stay length;
Duration of
mechanical
ventilation;
Need for renal
replacement
therapy;
Mortality

Treatment Groups

Vitamin C treatment
protocol
n=47
Standard treatment
n=47

Vitamin C treatment
protocol
n=14
Standard treatment
n=14

Vitamin C treatment
protocol
n=50
Standard treatment
n=50

Table 3. Overview of studies included in this review

Study 1 - Hydrocortisone, Vitamin C and Thiamine for the Treatment of Severe Sepsis
and Septic Shock: A Retrospective Before-After Study. Marik et al.11
Objective: The purpose of this study was to compare the outcomes and clinical course of
septic patients treated with a regimen of intravenous vitamin C, hydrocortisone, and
thiamine compared with standard treatment of patients with sepsis.
Study Design: This study was an Electronic Health Record (EHR) based retrospective
before and after study performed at Sentara Norfolk General Hospital. The primary
outcome measure of this study was hospital survival. The secondary outcome measure
included duration of vasopressor therapy. There were 94 total cases analyzed in this study.
Between January 2016 and July 2016, 47 patients with a primary diagnosis of sepsis or
septic shock were treated with an experimental vitamin C protocol (Table 8). The control
group consisted of 47 patients admitted to the same ICU between June 2015 and December
2015 using the same inclusion and exclusion criteria (Table 4). The authors stated there
were no significant changes in ICU protocols, referral patterns, or patient populations
between the time period during which the control group and the vitamin C treatment group
were observed. The only difference stated to exist between treatment and control groups is
the addition of the vitamin C treatment protocol (Table 8). However, certain patients in the
control period were noted to have been treated with hydrocortisone (50 mg every 6 hours)
per guidelines or a physician's discretion.
The diagnoses of severe sepsis and septic shock were based upon the 1992
American College of Chest Physicians/Society of Critical Care Medicine Consensus
Conference definitions. The search for patient cases for each group was performed using the
hospital’s EHR system using the inclusion and exclusion criteria (Table 4).
The standard management of a patient in septic shock consisted of empiric broad
spectrum antibiotics, which were adjusted as culture results were returned and the
patient's clinical picture changes. Norepinephrine was the vasopressor of choice for
vasopressor strategy and was titrated to achieve a mean arterial pressure (MAP) of greater
than 65 mmHg. If norepinephrine proved insufficient to achieve adequate MAPs,
vasopressin, phenylephrine, or epinephrine was used.
Study Design (Marik)
Inclusion Criteria

Exclusion Criteria

Patients admitted to ICU with primary diagnosis of severe
sepsis or septic shock with a procalcitonin of ≥ 2ng/ml.

Patients < 18, pregnant patients,
patients with limitations of care

Table 4. Inclusion and exclusion criteria for the Marik et al study
Study Results: The patients in the treatment group had a significantly reduced mortality
(8.5%) when compared with the control group (40.4%, p < 0.001). The duration of
vasopressor administration required to maintain a MAP of 65 mmHg or higher was
significantly shorter in the vitamin C treatment group (18.3 hours) than the control group
(54.9 hours, P<0.001). No statistically significant difference was noted between groups in
the length of ICU stay. The report states that patients in the vitamin C treatment group could
be predictably weaned off vasopressors 2-4 hours after beginning vitamin C treatment.

Study Critique: There are a number of drawbacks to how this study was conducted.
Primarily the before-and-after study design is considered non-experimental due to the high
likelihood that the control and experimental groups lack equivalency of conditions. This is
in part due to the control and treatment trials taking place during different periods of time.
While an attempt was made to ensure that conditions were the same for both periods of
time, there may be subtle differences in the ICU that went undetected. A before-and-after
study does provide useful evidence of the effectiveness of an intervention but lacks the
ability to test efficacy. Another significant weakness of this study is the lack of blinding. The
individuals administering the vitamin C treatments were not blinded and neither were the
researchers accessing the EHR retrospectively.
The unblinded nature of this study design casts suspicion of bias on the part of the
personnel administering the medications and charting the resultant patient response. The
treatment regimen of vitamin C, corticosteroids, and thiamine presents a problem for
assessing the clinical efficacy of vitamin C as an isolated factor. For the purposes of
investigating the clinical usefulness of vitamin C compared to existing standard treatments,
this study falls a bit short due to the trials having been conducted during different time
periods and the confounding presence of hydrocortisone and thiamine in the treatment
group. Nevertheless, this study does present intriguing data and certainly adds clinical
research data to an evolving area of active research.
Study 2 - Effect of high-dose ascorbic acid on vasopressor requirement in
septic shock. Zabet et al. 12
Objective: The purpose of this study was to evaluate the effects of high dose vitamin C on
hemodynamic parameters in surgical patients who meet septic shock criteria.
Study Design: This study is a double blind randomized controlled trial performed in the
ICU of Imam Khomeini Hospital in Tehran, Iran. This study was specifically looking at post
surgical patients presenting with septic shock.
The treatment of septic shock in the ICU during the course of this study followed
recommendations by the Surviving Sepsis Campaign.13 Crystalloid fluids were used for fluid
resuscitation to maintain arterial pressures. Norepinephrine was the vasopressor of choice
to maintain mean arterial pressure of over 65 mmHg when fluid resuscitation alone was
insufficient. Antibiotic treatments were administered per hospital recommendations.
Continuous IV fentanyl administration was used as the sedation protocol.
The primary outcomes measured were the dose and duration of vasopressor therapy
required for each patient. The duration of ICU stay and 28 day mortality were secondary
outcomes. Many demographic and laboratory data were collected initially to demonstrate
equivalency between the treatment and control groups. In addition to standard
demographic information, the researchers included a medical history of pre-existing
diseases, the cause of ICU admission, and extensive laboratory and test results such as
electrolyte levels, blood urea nitrogen, and serum creatinine. Initial Acute Physiology and
Chronic Health Evaluation II (APACHE II) and SOFA scores were calculated using laboratory
data and vital signs.
Patients who met inclusion criteria (Table 5) were separated into either the treatment
or control group using permuted block randomization. This method of randomizing
individuals in a clinical trial involves taking a series of blocks from which an equal number
of patients is assigned to randomly. The block randomization in this study consisted of
seven blocks of four patients each for a total of 28 patients (14 in each group). No patients

were excluded during the trial. The diagnosis of septic shock was based upon the definition
provided by the Surviving Sepsis Campaign and the following criteria:
1. Presence of systemic inflammatory response (Table 1)
2. Suspected or proven infection
3. Presence of sepsis induced organ dysfunction (refer to SOFA score criteria, Table 2)
The Vitamin C treatment group received 25 mg/kg Vitamin C in 50 ml of dextrose 5%
solution IV over 30 minutes every 6 hours for 72 hours (Table 8). The control group
received a 50 ml IV infusion of dextrose 5% over 30 minutes. These treatments were mixed
in the pharmacy. Researchers, patients, and those caring for the patients were all blinded to
who was receiving the treatment or placebo.
Study Design - Zabet et al
Inclusion Criteria
•
•
•

18-65 years old
Postoperative surgical patients with
diagnosis of septic shock
Demonstrated need for vasopressors

Exclusion Criteria
•
•
•

Concomitant use of other antioxidants
Corticosteroid administration
Any contraindication for high-dose
ascorbic acid

Table 5. Inclusion criteria for the Zabet et al study. No exclusion criteria was explicitly
stated in this study.
Study Results
Demographics: No statistically significant difference was noted between treatment
and control groups for demographic data or clinical characteristics. SOFA and APACHE II
scores, laboratory tests, and hemodynamic status were all statistically equivalent between
groups during patient enrollment in this study.
Treatment efficacy: Duration of vasopressor therapy was significantly lower in the
Vitamin C treatment group when compared with control (P = 0.0007). The 28-day mortality
was significantly lower in the Vitamin C treatment group (P = 0.009). No statistically
significant difference was noted between treatment and control groups for length of ICU
stay. The mean required vasopressor doses were lower for the Vitamin C group (7.44
mcg/min) than for the treatment group (13.79 mcg/min, p = 0.004).
The article compared the treatment and control groups on numerous demographic
and clinical features. APACHE II and SOFA scores were also calculated for patients in each
group prior to treatment. No statistical significant difference was found between groups on
any of these measures.
Study Critique: This study is a well-designed, double blind, randomized controlled trial.
Researchers and those caring for the patient were effectively blinded. The inclusion criteria
is clear, however exclusion considerations are not explicitly stated. The plethora of
demographic and clinical data that the researchers compared to show equivalency between
the treatment and control groups does serve to greatly strengthen this study. The primary
drawback of this study is the low number of enrolled participants with 14 patients per
group. This study would benefit immensely from increased power. With a low number of
participants in this study there is an increased possibility of a type 2 error. An additional
drawback to this study was the short duration of the intervention. A longer course of
Vitamin C treatment beyond the 72 hours used in this study is certainly worth further
investigation. Baseline serum Vitamin C levels are not measured in this trial. The authors of

this study do point out that it would be beneficial to obtain baseline Vitamin C levels in
patients prior to therapy. A final note is that only postsurgical patients diagnosed with
septic shock are included in this study. Post surgical patients with septic shock are a subset
of all patients with septic shock. It is useful to assess this population specifically, however
there is a possibility that these results are not applicable to all patients with septic shock.
Study 3- Early adjuvant IV Vitamin C treatment in septic shock may resolve the
vasopressor dependence. Habib et. al.14
Objective: The purpose of this study was to evaluate the role of early intravenous high
doses of Vitamin C, compared to standard treatment alone, as adjuvant therapy in patients
with septic shock. The primary outcomes investigated were the duration of time on
vasopressors, duration of ICU stay, days of mechanical ventilation, and need for renal
replacement therapy. ICU-mortality was a secondary outcome.
Study design: This was a randomized controlled trial with a total of 100 patients conducted
in the intensive care unit (ICU) in Alexandria University hospital in Egypt. The 100 patients
were randomized using the even odd randomization technique to receive either
conventional treatment with adjuvant Vitamin C (n=50) or conventional treatment alone
(n=50). Inclusion and exclusion criteria for the study can be found in Table 6.
Upon admission to the ICU, patients in the Vitamin C group received 1.5g
intravenous Vitamin C (ascorbic acid, Cevarol) every 6 hours until discharge from the
hospital. The primary outcomes measured were the need for organ supportive measures
including duration of vasopressor usage, mechanical ventilation and renal replacement
therapy and also the length of ICU stays. The secondary outcome measured was in-ICU
mortality. All patients were followed up from the day of enrollment until the day of
discharge. The SOFA score was evaluated on day 1 of admission and every day thereafter
until discharge or death.

Study Criteria - Habib et al
Inclusion Criteria

Exclusion criteria

· Males and females >18 years of age
· Admitted to the critical care department
· Diagnosis of septic shock as defined by the 3rd
International Consensus Definition for Septic Shock2
· At least one positive blood culture

· Pregnant and lactating mothers
· History of oxalate nephrolithiasis
· Glucose- 6-phosphate
dehydrogenase G6PD deficiency
· Paroxysmal nocturnal
hemoglobinuria
· Hereditary hemochromatosis were
· Any other type of shock state or
patients with mixed type of shock

Table 6. Inclusion and exclusion criteria for the Habib et al study.

Study Results
Demographics: Of the 50 patients receiving intravenous Vitamin C therapy, the average age
was 42.78 with 28 males and 22 females. The control group was comprised of 30 males and
20 females with an average age of 41.7 years. The SOFA scores were calculated prior to
treatment with no statistically significant difference between the treatment group and
control group. Mean arterial pressure, heart rate, respiration rate, and temperature were
also documented for each group with no statistically significant difference between the two
groups.
Treatment efficacy: The primary end point for the Habib et al study was the duration of
vasopressor usage for septic patients in the ICU. Patients in the treatment group were on
vasopressors for an average of 2.30 ± 1.2 days compared to the control group, which were
on vasopressors for an average of 6.50 ± 2.57 days. The difference in duration of
vasopressor usage between the two groups was statistically significantly significant with a p
value of 0.001.
The total number of days spent in the ICU was an additional primary
endpoint. Patients in the treatment group spent an average of 10.00 ±5.50 days in the ICU,
with the median being 12 days. The control group spent an average of 14.10 ±6.47 days in
the ICU with a median duration of 16 days. The difference in ICU stay was statistically
significant with a P value of 0.04.
Other primary endpoints evaluated were the total days requiring mechanical
ventilation and the need for renal replacement therapy. For the Vitamin C group, average
time spent on mechanical ventilation was 4.60±2.08 days and the need for renal
replacement therapy occurred in 30% of the group. In the control group the average
duration of mechanical ventilation was 7.87±3.01 days with a need for renal replacement
therapy occurring in 26%. There was no statistically significant difference between the
groups for either measure, with a p value of 0.187 for mechanical ventilation and a p value
of 0.412 for renal replacement therapy.
The secondary endpoint for the study was ICU mortality. There was no statistically
significant difference between the treatment group and control group for mortality, with a p
value of 0.138. Of the 50 patients in the treatment group, 12 eventually died of sepsis
related complications resulting in a mortality rate of 24%. In the control group, 18 patients
died resulting in a mortality rate of 36%.
Study Critique: Strengths of this study included randomization of participants, minimal
demographic variation between the two groups, and a relatively large sample size. The
randomization of the two groups resulted in no statistically significant differences with
regards to their demographics, baseline vital signs, and initial lab work. Although 100
patients is not a large sample size by most standards, this is a large study size compared to
other similar studies evaluating the use of Vitamin C in sepsis treatment. However, the
authors did not mention power calculations, which contributes to the limitations of the
study.
The researchers attempted to address confounding variables between the two
treatment groups in their results section. They explicitly stated that there was no
statistically significant difference between the two groups in the source of the patient’s
sepsis. However, the p value they used for this calculation was p=0.088, which is not
statistically significant. Additionally, the author claims that cultures in both groups most
commonly grew out gram-negative organisms, with a p value of 0.551. The author did not

address how different sources of sepsis and different causative organisms may impact the
severity of septic shock and the effectiveness of the Vitamin C protocol.
Perhaps the largest weakness of the study was that baseline Vitamin C levels were
not obtained prior to therapy. This introduces the possibility that the control group had
collectively lower baseline levels of Vitamin C, accounting for the longer duration of
vasopressors and longer ICU stay. For future studies, baseline levels of Vitamin C should be
obtained prior to therapy in order to compare pre and post levels of Vitamin C with the
treatment outcome.
In this study, SOFA scores were used in the baseline workup and to evaluate the
trends throughout the course of the patient’s illness. The author did not include these
scores in the research article. In addition to vasopressor duration and mortality, a
comparison between the trends of the SOFA scores of the treatment group and the control
group should be a consideration for future studies in order to have objective evidence to
assess patients’ improvement.
An additional weakness of the study is that it was not blinded, which introduces the
potential for bias in the evaluation of the outcomes. While Vitamin C in low doses is
considered a benign therapy in most patients, the authors did not address potential harms
of large doses of Vitamin C therapy in septic shock. Renal failure and chronic kidney disease
impair the body’s excretion of Vitamin C and can lead to the build up of insoluble oxalate
which can accumulate and cause failure in multiple organs throughout the body. In future
studies, the outcomes of Vitamin C use in patients with renal failure should be studied.15
Lastly, the author does not define what the conventional sepsis treatment is at the
hospital. He states that the hospital protocol for sepsis treatment was used, however, the
exact sepsis protocol should be defined in order to optimize reproducibility of the study.

Study

Group

Marik
2016

Zabet
2016

Habib
2017

Duration of
Vasopressor Use
(hours)

Control

54.9 (±28.4)

Ascorbic
Acid Group

18.3 (±9.8)

Control

71.57 (±1.6)

Ascorbic
Acid Group

49.64 (±25.67)

Control

156 (±64.68)

Ascorbic
Acid Group

55.2 (±28.8)

p

< 0.001

Length of
ICU Stay
(days)
4 (4-10)

p

N/A

4 (3-5)

=
0.0007

20.57
(±13.04)

14.10 (±6.47)

19
(40.4%)

p

<
0.001

4 (8.5%)

=
0.85

21.45
(±10.23)

= 0.001

Mortality

9
(64.28%)

=
0.009

2
(14.28%)

=
0.04

10.0 (±5.5)
days

18 (36%)

=
0.138

12 (24%)

Table 7. Duration of vasopressor use, length of ICU stay, and mortality outcome data for
each of the studies.

Study

Vitamin C protocol

Control

Marik

•
•
•

IV Vitamin C 1.5gm every 6 hours for 4 days
IV Hydrocortisone 50mg every 6 hours for 7 days
IV Thiamine 200mg every 12 hour for 4 days

Standard ICU treatment of severe
sepsis and septic shock.

Zabet

25 mg/kg IV ascorbic acid every 6 hours for 72 hours

Standard treatment plus placebo

Habib

1.5 gm IV ascorbic acid every 6 hours in first 24 hours after
ICU admission plus conventional sepsis treatment

Conventional sepsis treatment

Table 8. Vitamin C treatment protocols for each of the studies assessed. For each of the
studies, the Vitamin C treatment occurred as an adjunct to standard treatments. Marik et al
performed the control and treatment phases of study at separate times. Zabet et al used a
placebo to perform a double blind randomized controlled trial.

Figure 2. Duration of vasopressor use outcome data for all three studies assessed in this
review. All three studies showed a statistically significant reduction in the duration of
vasopressor use (P < 0.05).

Figure 3. Mortality outcome data for all three studies assess in this review. Marik et al and
Zabet et al both showed a statistically significant decrease in mortality (P < 0.05). Habib et
al failed to show a statistically significant decrease in mortality.

Number Needed to Treat
Zabet

Died

Survived

Vitamin C Treatment Group

2

12

Control Group

9

5

Habib

Did Not Survive

Survived

Vitamin C Treatment Group

12

38

Control Group

18

32

Combined Studies Overall

Did Not Survive

Survived

Vitamin C Treatment Groups

14

50

Control Groups

27

37

NNT = 2

NNT = 8

NNT = 5

Table 9. Number needed to treat based on mortality data for each study and the combined number
to treat. The Marik et al study was not included due to study design.

DISCUSSION
Sepsis is the result of a systemic infection and is a major health concern with
considerable associated morbidity and mortality. The massive vasodilatory response to the
infection results in poor perfusion of organs and tissues leading to multi organ system
damage. Current therapies are aimed at treating the infection in addition to maintaining
adequate perfusion. This is accomplished by using broad-spectrum antibiotics, fluid
resuscitation, and vasopressors to maintain a mean arterial pressure of greater than 65
mmHg. Recently there has been interest in the addition of Vitamin C to the standard
treatment of septic shock. The aim of this review was to investigate the role of Vitamin C in
the treatment of septic shock by analyzing three recent studies that compared Vitamin C
usage to standard treatment. Each of these studies compared the efficacy of adding Vitamin
C to standard treatments by using vasopressor requirements, length of ICU stay, and
mortality as comparable outcomes. An overview of the findings of the studies in this review
is provided in Table 3.
All three studies demonstrated a significant reduction in vasopressor dependency
within the Vitamin C treatment group. This outcome is not surprising as ascorbic acid is a
cofactor for the enzymes involved in the synthesis of endogenous vasopressors. Sepsis
results in significant oxidative stress resulting in a reduction of Vitamin C levels and
therefore a reduction in the synthesis of norepinephrine and vasopressin. This is a

significant finding, however, based on these articles alone it is unclear whether the
reduction in vasopressor dependency is associated with a decrease in mortality.
There was conflicting evidence among the studies regarding the duration of ICU stay
and reduction of mortality in the Vitamin C treatment group. Marik et al and Zabet et al
found that the addition of Vitamin C to standard sepsis treatment resulted in a statistically
significant reduction in mortality, with p values of 0.001 and 0.009 respectively. Although
Marik et al. did show a statistically significant reduction in mortality, due to the low power
of the study and it’s quasi-experimental design, it is difficult to determine the validity of this
result. Habib et al found no statistically significant difference in mortality with the addition
of Vitamin C, with a p value of 0.138. These conflicting results could be due to the low
power of all three studies.
The most notable limitation to this review is the low power within each of the
studies. The small sample size in these trials and lack of significant randomized controlled
trials on this topic are likely due the lack of knowledge about adverse effects associated
with the addition of Vitamin C in septic shock. A recent Phase 1 safety trial was conducted
in 2014 by Fowler et al to examine the safety of Vitamin C in the treatment of sepsis. The
results found by this trial demonstrated that the addition of Vitamin C in septic shock was
safe and well tolerated with no adverse events.16 With these results and the promising
results found in the three studies in this review, there will hopefully be larger randomized
controlled trials conducted in the future to reveal more conclusive outcomes for the use of
Vitamin C therapy in septic shock.
Number needed to treat (NNT) is a metric used to assess the impact of a therapy. It
is the number of patients that must be treated for one patient to benefit from the therapy
over a specified time. Calculated from mortality data in Table 9, the NNT for the Zabet et al
study was 2. This means that for every 2 patients with septic shock treated with the
regimen in Table 8 for 72 hours, there was a patient who had a reduced 28 day mortality.
For the Habib et al study, the NNT was 8, meaning that for every 8 patients treated with the
regimen in Table 8 for 24 hours after ICU admission, there was a patient who had reduced
ICU mortality. The NNT was not calculated for the Marik study due to this study being a
before-and-after study and not a randomized controlled clinical trial. Combining the
mortality data from the Zabet and Habib studies results in an NNT of 5 (Table 9). The NNT
measure does require that the studies be equivalent in the duration of time for which the
outcome is observed. The Habib et al study does not include enough information on the
mortality outcome measure to assure equivalence in time. Therefore these studies may not
be directly comparable by using the NNT measure. Nevertheless, the NNT measures from
these studies individually and combined do suggest possible benefit in the treatment of
septic shock, a condition which has a very poor prognosis
CONCLUSION
These studies appear to demonstrate improvements in patient outcomes when
standard treatments of septic shock are supplemented with high doses of Vitamin C. Each of
the studies assessed indicates a significant reduction in vasopressor requirements for septic
patients when they are treated with high doses of Vitamin C as adjunct therapy to standard
treatment. Two of the three studies showed a significant reduction in mortality. These
studies suffer from small sample sizes, and only two of them are randomized controlled
trials. Considerations for future studies include the measurement of Vitamin C levels prior
to and during treatment and the comparison of SOFA scores between the treatment and
control groups. If the results of these studies can be replicated in large scale randomized
controlled trials, certainly there would be a case for Vitamin C to be included in the
standard treatment of septic shock.
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